Latest News and Press Releases

First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center  Preclinical animal studies of BetaBart (RV-01) have...

Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases  Interim...

Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received...

92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent...

RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons SYDNEY, Nov. ...

Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in brain metastases compared to MRI Phase 2b clinical trial expected to complete enrollment and have...

Data Safety Monitoring Committee approves advancing to a higher dose of 90mCi The first two Cohorts’ patients show tumor uptake and a favourable safety profile SYDNEY, Nov. 12, 2025 (GLOBE...

Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from solid tumors, confirming proof-of-concept with Phase 2 topline results...

RAD has received firm commitments for a A$35 million capital raising via an institutional private placement to new Australian and international institutional and sophisticated investors at A$0.03 per...

SYDNEY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative...